In particular, loss of function mutations in SMARCA4 are enriched in subsets of multiple malignancies, with the highest prevalence of homozygous mutations occurring in non-small cell lung cancer (NSCLC)6,7. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.